Financing

LaNova Medicines, as well as other Chinese RNA interference specialists and developers of stem cell-based therapies, were among those securing new funds from venture capital and private equity firms over the past few months.

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.

During Q3, biopharmas brought in an aggregate $17bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.1m.

Biostar plans to raise up to $41m through a Hong Kong IPO, which help the Chinese chemotherapy specialist progress lead asset utidelone for various oncology indications.

Three $1bn+ alliances were penned in September.

Xbrane Biopharma is on the clock to bring in a licensing partner for one of its two biosimilar candidates in order to fulfil its short-term working capital requirements. The Swedish firm has revealed that a deal for one appears close, as it also reached an agreement for more time to put pen to paper.

With marketed European biosimilar rivals already making a dent in Stelara’s sales performance, Johnson & Johnson mourns its blockbuster’s upcoming loss of exclusivity across the Atlantic Ocean.

Charles Cooper, CMO of the diagnostics firm bioMérieux, talks to In Vivo about the vital nature of partnerships to fight the global AMR crisis.

Backed by AI and former FDA official Janet Woodcock, Every Cure is set to identify approved drugs for patients who don’t have treatment options around the world.

While oncology and discovery-stage assets accounted for the majority of R&D projects supported by a Korean state fund this year, new modalities such as ADCs and TPDs are emerging.